Device Trial Radar · NCT02487160
Clinical Evaluation of the Lenstec SBL-3 Multifocal Intraocular Lens
Last checked: Nov 19, 2026Latest source record: May 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
499
Actual
Start
Aug 2015
Primary completion
Aug 2019
Study completion Aug 2019
Sponsor
- Lead sponsor
- Lenstec IncorporatedNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 1, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and performance of the SBL-3 intraocular lens.
Conditions
- Cataracts
- Presbyopia
Interventions
SBL-3 multifocal intraocular lensDevice
The SBL-3 intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
Control monofocal intraocular lensDevice
The Control intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
Primary outcomes
What the sponsor says the trial is designed to measure.
- photopic, distance corrected, monocular near visual acuityTime frame: 1 year following implantation
- presence or absence of adverse eventsTime frame: 1 year following implantation
- photopic, distance corrected, monocular intermediate visual acuityTime frame: 1 year following implantation
1 more outcomes with a free account
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Eye Center South
Dothan, Alabama
Shepard Eye Center
Santa Maria, California
Cape Coral Eye Center
Cape Coral, Florida
10 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.